Prof Ben Tran
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
459 Scholarly works
11 Projects
HIGHLIGHTS
2026
Journal article
Extracranial, Extragonadal Germ Cell Tumors: A Multicenter Australian Case Series
DOI: 10.1111/ajco.700832026
Journal article
Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro).
DOI: 10.1016/j.esmorw.2025.1006772026
Journal article
ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial.
DOI: 10.1200/jco.2026.44.7_suppl.8092026
Journal article
Primary retroperitoneal lymph node dissection for clinical stage IIA/B metastatic seminoma: A multi-centre Australian experience.
DOI: 10.1200/jco.2026.44.7_suppl.6012022
Research grants (ARC, NHMRC, MRFF)
Targeting Cold Tumours With Triple Therapy
2019
Research Grant
PRECEPT - PRostatE CancEr Prognosis and Treatment
2017
Research Grant
Combination of Radionuclide 177lu-Psma Therapy With Pembrolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
RECENT SCHOLARLY WORKS
2026
Journal article
Treatment patterns and survival outcomes among lutetium 177–experienced patients with metastatic castration-resistant prostate cancer.
DOI: 10.1200/jco.2026.44.7_suppl.692026
Journal article
Real-World Outcomes in Advanced Clear Cell Renal Cell Carcinoma: A Retrospective Analysis Comparing New Zealand and Australian Cohorts
DOI: 10.1200/GO-25-003842026
Journal article
A0591 Longitudinal assessment of urine tumor DNA in high-risk non-muscle invasive bladder cancer patients
DOI: 10.1016/s0302-2838(26)00642-12026
Journal article
Preliminary phase 1 dose escalation results of VIR-5500 (AMX-500), a dual-masked PRO-XTEN T-cell engager, in metastatic castration resistant prostate cancer (mCRPC).
DOI: 10.1200/jco.2026.44.7_suppl.172026
Journal article
Initial results from CLIMATE, a prospective cohort study assessing the clinical utility of miR-371a-3p (miR-371) as a marker of minimal residual disease (MRD) in clinical stage 1 testicular germ cell tumour (TGCT): ANZUP 1906.
DOI: 10.1200/jco.2026.44.7_suppl.5862026
Journal article
Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody.
DOI: 10.1158/1078-0432.CCR-25-3447
RECENT PROJECTS
2024
Research grants (other domestic)
Stereotactic Ablative Body Radiotherapy (SABR) for 4 Gynaecologic Metastases
2024
Research grants (ARC, NHMRC, MRFF)
P3BEP Trial - Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours - An Australian-Led, International Randomised Trial